(19)
(11) EP 2 146 732 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
26.12.2012 Bulletin 2012/52

(45) Mention of the grant of the patent:
31.10.2012 Bulletin 2012/44

(21) Application number: 08742733.2

(22) Date of filing: 10.04.2008
(51) International Patent Classification (IPC): 
A61P 1/08(2006.01)
(86) International application number:
PCT/US2008/004640
(87) International publication number:
WO 2008/124183 (16.10.2008 Gazette 2008/42)

(54)

METHODS OF TREATING OR PREVENTING EMESIS USING GROWTH HORMONE SECRETAGOGUES

VERFAHREN ZUR BEHANDLUNG ODER PRÄVENTION VON ERBRECHEN MIT WACHSTUMSHORMON-SEKRETAGOGA

PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DE VOMISSEMENT METTANT EN UVRE DES SÉCRÉTAGOGUES D'HORMONES DE CROISSANCE


(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: 10.04.2007 US 922742 P

(43) Date of publication of application:
27.01.2010 Bulletin 2010/04

(73) Proprietor: Helsinn Healthcare SA
6912 Lugano-Pazzallo (CH)

(72) Inventors:
  • MANN, William, R.
    Sparta, NJ 07871 (US)
  • POLVINO, William, J.
    Tinton Falls, NJ 07724 (US)

(74) Representative: Zardi, Marco et al
M. Zardi & Co. S.A. Via Pioda 6
6900 Lugano
6900 Lugano (CH)


(56) References cited: : 
WO-A1-01/34593
US-A1- 2007 021 331
US-B1- 6 303 620
US-B2- 6 576 648
US-A1- 2005 277 677
US-A1- 2007 037 751
US-B1- 6 919 315
   
  • LIU Y-L ET AL: "Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents." September 2006 (2006-09), CANCER CHEMOTHERAPY AND PHARMACOLOGY SEP 2006 LNKD- PUBMED:16435157, VOL. 58, NR. 3, PAGE(S) 326 - 333 , XP19423295 ISSN: 0344-5704 * See abstract: ghrelin (a growth hormone secretagogue) alleviates dyspepsia (which includes vomiting) associated with chemotherapy *
  • RUDD JOHN A ET AL: "Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin." 9 January 2006 (2006-01-09), NEUROSCIENCE LETTERS 9 JAN 2006 LNKD- PUBMED:16182445, VOL. 392, NR. 1-2, PAGE(S) 79 - 83 , XP25024067 ISSN: 0304-3940 * See abstract: ghrelin, which is a growth hormone secretagogue provides a novel approach in the treatment of emesis *
  • PAUL, BERNHARD J. ET AL: "A Practical Synthesis of the Pseudotripeptide RC - 1291" ORGANIC PROCESS RESEARCH & DEVELOPMENT , 10(2), 339-345 CODEN: OPRDFK; ISSN: 1083-6160, 2006, XP002590175
  • YANG L ET AL: "1-[2(R)-(2-amino-2-methylpropionylamino)- 3-(1H-indol-3-yl)propionyl]- 3-benzylpiperidine-3(S)-carboxylic acid ethyl ester (L-163,540): a potent, orally bioavailable, and short-duration growth hormone secretagogue." 2 July 1998 (1998-07-02), JOURNAL OF MEDICINAL CHEMISTRY 2 JUL 1998 LNKD- PUBMED:9651148, VOL. 41, NR. 14, PAGE(S) 2439 - 2441 , XP002590176 ISSN: 0022-2623 * See preparation of L 163,540 a compound structurally related to RC-1291, and its activity as growth hormone secretagogue *
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).